Demographic and clinical characteristics of the study population summarized by type of treatment and according to the gender.

<p>Data are shown as absolute (n) and relative (%) frequencies for categorical variables and as means (±SD) for continuous variables. P-values refer to the statistical significance of the difference across the four treatments or between the two genders.</p><p>BMI: Body Mass Index; CV: Cardiovascular; SD: Standard Deviation.</p><p>Demographic and clinical characteristics of the study population summarized by type of treatment and according to the gender.</p

1-year survival rate according to treatment and gender.

<p>Kaplan-Meier cumulative survival curves during 1-year of follow-up in men and women enrolled in the SMILE Program and treated with zofenopril, other angiotensin-converting-enzyme inhibitors (ACEIs) or placebo. CV: Cardiovascular.</p

1-year incidence of cardiovascular events according to treatment and gender.

<p>Overall incidence (%) of major cardiovascular (CV) events during the 1-year follow-up in men (open bars) and women (full bars) treated with zofenopril, placebo or other angiotensin-converting-enzyme inhibitors (ACEIs). P-values refer to the statistical significance of between-gender difference.</p

1-year risk of cardiovascular events according to treatment and gender.

<p>Effect of zofenopril vs. placebo or other angiotensin-converting-enzyme inhibitors (ACEIs) on the 1-year risk of major cardiovascular (CV) events according to gender in the SMILE Program. Data are reported as odds ratio and 95% confidence interval, with corresponding p value.</p